Table 1 Baseline characteristics
Variables | All (N = 30) | Men (N = 19) | Women(N = 11) | Reference value (men/women) |
|---|---|---|---|---|
Age, median (range) | 74 (70–82) | 74 (70–82) | 76 (70–80) | |
ECOG-PS, n (%) | ||||
0 | 11 (36.7) | 7 (36.8) | 4 (36.4) | |
1 | 18 (60.0) | 12 (63.2) | 6 (54.5) | |
2 | 1 (3.3) | 0 (0.0) | 1 (9.1) | |
Stage, n (%) | ||||
IIIA or IIIB | 1 (3.3) | 1 (5.3) | 0 | |
IV or postoperative reccurence | 29 (96.7) | 18 (94.7) | 10 (100) | |
Tumor Histology, n (%) | ||||
Adenocarcinoma | 21 (70.0) | 13 (68.4) | 8 (72.7) | |
Other non-small-cell lung cancer | 9 (30) | 6 (31.6) | 0 | |
Chemotherapeutic regimen, n (%) | ||||
Cytotoxic regimen | 24 (80.0) | 17 (89.5) | 7 (63.6) | |
Targeted regimen | 6 (20.0) | 2 (10.5) | 4 (36.4) | |
Never smoke, n (%) | 9 (30.0) | 0* | 9 (81.2) | |
Comorbidities, n (%) | ||||
Chronic obstructive pulmonary disease | 10 (33.3) | 7 (36.8) | 3 (27.3) | |
Type 2 diabetes | 6 (20.0) | 5 (26.3) | 1 (9.1) | |
Cerebrovascular disease | 4 (13.3) | 4 (21.1) | 0 | |
Cardiovascular disease | 1 (3.3) | 0 | 1 (9.1) | |
Body composition | ||||
Body-mass index (kg/m2) | 21.1 ± 3.4 | 21.6 ± 3.5 | 20.2 ± 3.1 | |
Lumbar skeletal muscle index (cm2/m2) | 41.2 ± 7.8 | 44.5 ± 7.6* | 35.4 ± 4.1 | |
Skeletal muscle depletiona, n (%) | 20 (66.7) | 10 (52.6)* | 10 (90.9) | 17.2/ 19.9 [26] |
Cancer cachexiab, n (%) | 19 (63.3) | 11 (57.9) | 8 (72.7) | |
Physical function | ||||
Hand grip strength (dominant side, kg) | 29.3 ± 8.5 | 33.9 ± 7.1* | 21.7 ± 4.1 | 32/ 20 [24] |
Shuttle walk distance (m) | 326.0 ± 127.9 | 338.4 ± 143.0 | 304.5 ± 99.2 | 360–400 [25] |